February 21 2012 Red Mountain Resources CEO Alan Barksdale on Business Talk Radio and News Program The Bill Chippas Show
that features balanced investment strategies-options and stocks to buy plus Energy Market,  Forex and Precious Metals Analysis and News.

Podcast

Share and Enjoy

Podcast

Thursday February 16th , 2012 Podcast, Balanced Investment Strategies-Options and Stocks To Buy – Forex
- Precious Metals Analysis and News.

Share and Enjoy

Podcast

Dr. Steven Victor, the founder and Chief Executive Officer of IntelliCell BioSciences Inc. appeared on today’s broadcast of the business talk Radio, TV and News Program – The Bill Chippas Show – and gave insight on IntelliCell BioSciences Inc. For more information and insight on IntelliCell BioSciences, listen to our Tuesday February 14- 2012 Broadcast of the business Talk Radio , TV and News Program ‘The Bill Chippas Show’ with Dr. Steven Victor, the founder and CEO of IntelliCell BioSciences Inc. also get Investment strategies , market analysis and news , for additional information, visit http://www.intellicellbiosciences.com or call Princeton Research http://www.princetonresearch.com at 702-650-3000.

*Rule 17B Requirements — Disclosure of Payment for Investor Relations– Princeton Research has contracted to receive 10,000 restricted shares from IntelliCell BioSciences to do investor relations.

Share and Enjoy

Dr. Steven Victor, the founder and Chief Executive Officer of IntelliCell BioSciences Inc. will appear on tuesday’s broadcast of the business talk Radio , TV and news program – The  Bill Chippas Show – to give insight on IntelliCell BioSciences Inc, watch Tuesday’s Broadcast  of  ‘The  Bill Chippas Show’ from 10:05 AM ET to 11:00 AM –Live on WPSLTV.com  http://www.wpsltv.com and get Investment strategies , market analysis and news . You may also listen live at http://www.billchippasshow.com , call in your questions to 772-340-1590 email questions bill@billchippasshow.com.

Dr. Victor is a practicing celebrity dermatologist with over 20 years’ experience and has had guest appearances on 20/20, Good Morning America, The Today Show, etc., along with features in nationally published fashion/style magazines. Also Joining the show will be Joe Salvani to provide information and the investment potential of IntelliCell BioSciences Inc. (symbol SVFC)

IntelliCell BioSciences Inc., http://www.intellicellbiosciences.com (symbol SVFC) is a pioneering regenerative medicine company focused on the expanding regenerative medical markets. IntelliCell BioSciences develops a portfolio of products and services that targets a wide and diverse regenerative, preventative, and curative medical market including age related disease states to sports related injuries.

Dr. Victor is renowned in the field of Dermatology, pioneering some of the most effective and interesting treatments in skin rejuvenation today.  He has lectured around the world, consulted for numerous cosmetic companies, been featured in numerous magazines and various television and news segments.  Dr. Victor has developed numerous successful consumer products for distribution through the Cosmeceuticals and Prescription skin care channels.  Medicis (MRX/NYSE), a specialty pharmaceutical company that develops and markets products for the treatment of dermatological, aesthetic, and podiatric conditions, was initially launched successfully with 6 Rx products of Dr. Victor’s including Benzashave, a patented product.  Dr. Victor launched one of the first acne infomercials in 1992 and developed the products for the Cher Skin Care infomercial.  Dr. Victor has held numerous teaching appointments and holds a Bachelor of Arts degree from New York University and received his M.D. degree from New York College.

IntelliCell BioSciences Inc. has patent-pending process for a non-enzymatic method of deriving stromal vascular fraction from adipose tissue (your own fat).  IntelliCell’s process dramatically increases the yield by 10 to 20 times in manufacturing compared to methods in use today. These mixtures of cells have multiple functions and are highly integrated and it’s likely, more potent than the adipose stem cells by themselves.

IntelliCell BioSciences Inc offers Intellicell™, a treatment for the correction of lines, wrinkles, and dermal defects, as well as for various treatments, including anti-aging, scarring, burns, and non-healing wounds; stem cell product candidates for treating aging dermal skin; and product candidates in the areas of osteoarthritis, cartilage and meniscus regeneration, and general dermal regeneration, the applications for its product are wide and diverse, IntelliCell BioSciences, Inc. is based in New York, New York.

IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients. The company is also setting up Centers of Excellence where doctors can treat their patients.  IntelliCell announced last month it licensed its proprietary, patent pending technology to RegenaStem Inc., a Canadian Federally Incorporated Company, with offices in Ontario, The license calls for investing a minimum of $500,000 to a maximum of $1.5 million into IntelliCell BioSciences and paying royalties of 30% of net revenue.

IntelliCell BioSciences is also starting FDA IND clinical trials at major medical centers for clinical indication approval, some potential centers are; Emory, Georgia Tech, Mt Sinai Medical Center , NYU and Tulane.  IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities.

For more information and insight on IntelliCell BioSciences listen or watch tonight’s Broadcast  of  the business talk radio and TV program ‘The  Bill Chippas Show’ with Dr. Steven Victor, the founder and CEO of IntelliCell BioSciences Inc. from 6:05 PM ET to 7:00 PM –Live on WPSLTV.com  http://www.wpsltv.com, also get Investment strategies , market analysis and news , for additional information, visit http://www.intellicellbiosciences.com or call Princeton Research http://www.princetonresearch.com at 702-650-3000.

*Rule 17B Requirements — Disclosure of Payment for Investor Relations– Princeton Research has contracted to receive 10,000 restricted shares from IntelliCell BioSciences for investor relations.

Share and Enjoy

Terry Howlett CEO of Skinvisible Pharmaceuticals, http://www.skinvisible.com  appeared on the Bill Chippas Business Show -Talk Radio, TV and News Program Thursday February 9, Plus get  forex , equity investment, precious metals , crude oil anayisis and short term winning trades plus news.

Skinvisible Pharmaceuticals Symbol SKVI Skinvisible is a research-and-development company that licenses its proprietary formulations made with Invisicare®,  its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products.

 

Podcast

 

 

 

The Technology: Invisicare® offers numerous benefits including binding products to the skin for 4 hours+ and more, while resisting wash-off and rub-off. It also enhances the efficacy of ingredients, reduces irritation and can reduce costs. Skinvisible has developed a portfolio of 25+ skincare products using Invisicare and also works directly with companies to enhance their products, especially ones coming off patent. Learn more at www.invisicare.com .

Invisicare® holds active ingredients on the skin for extended periods of time resisting both wash off  and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare® patent.  Skinvisible Pharmaceuticals value lies in its ability to continually generate new IP (Intellectual. Property)   on dermatology and medical products formulated with Invisicare®. Development Agreement with Novartis, AG – A Major Opportunity In February 2011 Skinvisible entered into a feasibility agreement with Novartis Pharma AG, one of the largest pharmaceutical companies in the world. The purpose of the agreement was for Skinvisible to assess the technical feasibility of incorporating our Invisicare® technology into a new topical formulation with an undisclosed active ingredient (“the drug” or “API”). This formulation, still in development, would leverage the benefits of Invisicare by providing controlled release of the active ingredient. After the initial agreement was completed, a new feasibility agreement was entered into in November 2011 and Skinvisible continues to work in conjunction with Novartis to develop a viable formulation.

Skinvisible’s First Orphan Drug Application In 2011 Skinvisible entered into a new disease area which it had not addressed with any prior formulations. During our research and development process we discovered that we developed a product that may have a significant impact on those people that suffer from a debilitating disease called Netherton Syndrome. Netherton’s is a sub-type of ichthyosis which can affect any age and has some level of dry, thickened, scaly, cracked or flaky skin, with symptoms ranging from mild to life threatening.

In March 2011, Skinvisible submitted an application to the United States Orphan Drug Division in order to receive an Orphan Drug Product Designation for the Company’s product formulated with Invisicare to treat Netherton Syndrome. An adjunct to the original application was submitted in November 2011. In conjunction with this application, Skinvisible has also filed a patent application with the US Patent Office.

Skinvisible is pursuing this product as the United States Orphan Drug Act provides significant incentives to pharmaceutical companies to develop products for patients suffering from rare diseases. In the United States, a rare disease is defined as a condition which has less than 200,000 people with the disease. Receiving this orphan drug designation would add considerable value to this formulation which could result in a multimillion dollar license fee for Skinvisible.

The United States Orphan Drug Department responded to the application and indicated that (1) they accept Netherton Syndrome as an orphan disease and (2) they reviewed the data submitted and have requested that Skinvisible provide an additional specific set of data. Skinvisible is pleased with the feedback of the application so far and has begun putting into place a study that will meet the requirements specified by the FDA.

Dermatology Review Panel(TM) (“DRP”)  During 2011 Skinvisible announced that its DermSafe(R) Hand Sanitizing Lotion received the “Seal of Approval” from the Dermatology Review Panel(TM) (“DRP”). DRP is an independent panel of dermatologists that reviews scientific data for non-prescription products in order to authenticate a product’s claims.  DRP dermatologists evaluated Skinvisible’s scientific data and validated the following claims for DermSafe Hand Sanitizer: DermSafe is alcohol-free, it offers protection from harmful bacteria, it resists wash-off and it provides a moisture barrier for the hands. DermSafe, marketed by Alto Pharmaceuticals in Canada, will soon display the DRP Seal on its promotional materials and packaging.

European Patent Office (EPO) In late September 2011 Skinvisible  announced the European Patent Office (EPO) issued a Notice of Intent to Grant European patent application number 02752847.0 pertaining to Skinvisible’s drug delivery system, Invisicare, which  is a drug delivery technology used in prescription, over-the-counter and cosmeceutical products.  The comprehensive patent protects Invisicare®  composition ,  method of combining polymers to make the Invisicare complex and the skin / medical conditions Invisicare is used for.   This patent provides protection with claims that were also patented in the other Invisicare international patents. This patent approval is a significant milestone for Skinvisible as multi-national pharmaceutical and consumer goods companies seeking products for global distribution will now have protected products to license from Skinvisible on four continents, covering over twenty-two countries. Invisicare patent coverage now includes Europe, plus previously  announced India, Australia, China, Japan, Hong Kong, Korea, Canada and the USA.   Skinvisible continues to proactively build and strengthen its global intellectual property portfolio with twenty-eight patents pending. All patents with Invisicare® are owned by Skinvisible.

Women’s  Choice Pharmaceuticals LLC and ProCort(R) In July 2011 Skinvisible announced that its licensee, Women’s  Choice Pharmaceuticals LLC, a specialty pharmaceutical company based in Gilbert, Arizona,  launched ProCort(R), Skinvisible’s first prescription product in the United States. ProCort(R) is a topical treatment for hemorrhoids formulated with Skinvisible’s patented polymer delivery system Invisicare(R). Invisicare enhances the delivery of active ingredients by controlling the release and provides superior binding properties. ProCort(R) is made of a combination of hydrocortisone acetate and pramoxine hydrochloride. ProCort(R), launched this week, is a prescription product focused on the women’s health market.

Mr. Howlett founded Skinvisible, Inc. in 1998. With over 30 years of entrepreneurial, business management and market initialization experience, he drives and directs the Company’s development and technology vision. He is adept at guiding emerging and publicly traded start-up companies through the stages of capital formation, strategic planning and business growth; specializing in venture capital financing. Mr. Howlett’s diversified background includes senior management, marketing, and sales positions with both established and start-up companies. For More Information read the January 2012 Letter to shareholders.

Watch the Bill Chippas Show Business Talk Radio , TV and News Program for more about Skinvisible Pharmaceuticals plus forex , equity investments, precious metals analysis and short  term winning trades.

 

 

 

 

 

*Rule 17B Requirements — Disclosure of Payment for Investor Relations– Princeton Research has received 150,000 restricted shares from Skinvisible in exchange for investor relations services.

Share and Enjoy

Terry Howlett CEO of Skinvisible Pharmaceuticals, http://www.skinvisible.com appeared on the Bill Chippas Business Show -Talk Radio, TV and News Program Thursday February 9, get  forex , equity investment, precious metals , crude oil and short term winning trades plus analysis and news.

Podcast

Share and Enjoy

Terry Howlett CEO of Skinvisible Pharmaceuticals, http://www.skinvisible.com will appear on the Bill Chippas Business Show -Talk Radio, TV and News Program Thursday February 9, get  forex , equity investment, precious metals , crude oil and short term winning trades plus analysis and news.  

Skinvisible Pharmaceuticals Symbol SKVI Skinvisible is a research-and-development company that licenses its proprietary formulations made with Invisicare®,  its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products.

The Technology: Invisicare® offers numerous benefits including binding products to the skin for 4 hours+ and more, while resisting wash-off and rub-off. It also enhances the efficacy of ingredients, reduces irritation and can reduce costs. Skinvisible has developed a portfolio of 25+ skincare products using Invisicare and also works directly with companies to enhance their products, especially ones coming off patent. Learn more at www.invisicare.com .

Invisicare® holds active ingredients on the skin for extended periods of time resisting both wash off  and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare® patent.  Skinvisible Pharmaceuticals value lies in its ability to continually generate new IP (Intellectual. Property)   on dermatology and medical products formulated with Invisicare®. Development Agreement with Novartis, AG – A Major Opportunity In February 2011 Skinvisible entered into a feasibility agreement with Novartis Pharma AG, one of the largest pharmaceutical companies in the world. The purpose of the agreement was for Skinvisible to assess the technical feasibility of incorporating our Invisicare® technology into a new topical formulation with an undisclosed active ingredient (“the drug” or “API”). This formulation, still in development, would leverage the benefits of Invisicare by providing controlled release of the active ingredient. After the initial agreement was completed, a new feasibility agreement was entered into in November 2011 and Skinvisible continues to work in conjunction with Novartis to develop a viable formulation.

Skinvisible’s First Orphan Drug Application In 2011 Skinvisible entered into a new disease area which it had not addressed with any prior formulations. During our research and development process we discovered that we developed a product that may have a significant impact on those people that suffer from a debilitating disease called Netherton Syndrome. Netherton’s is a sub-type of ichthyosis which can affect any age and has some level of dry, thickened, scaly, cracked or flaky skin, with symptoms ranging from mild to life threatening.

In March 2011, Skinvisible submitted an application to the United States Orphan Drug Division in order to receive an Orphan Drug Product Designation for the Company’s product formulated with Invisicare to treat Netherton Syndrome. An adjunct to the original application was submitted in November 2011. In conjunction with this application, Skinvisible has also filed a patent application with the US Patent Office.

Skinvisible is pursuing this product as the United States Orphan Drug Act provides significant incentives to pharmaceutical companies to develop products for patients suffering from rare diseases. In the United States, a rare disease is defined as a condition which has less than 200,000 people with the disease. Receiving this orphan drug designation would add considerable value to this formulation which could result in a multimillion dollar license fee for Skinvisible.

The United States Orphan Drug Department responded to the application and indicated that (1) they accept Netherton Syndrome as an orphan disease and (2) they reviewed the data submitted and have requested that Skinvisible provide an additional specific set of data. Skinvisible is pleased with the feedback of the application so far and has begun putting into place a study that will meet the requirements specified by the FDA.

Dermatology Review Panel(TM) (“DRP”)  During 2011 Skinvisible announced that its DermSafe(R) Hand Sanitizing Lotion received the “Seal of Approval” from the Dermatology Review Panel(TM) (“DRP”). DRP is an independent panel of dermatologists that reviews scientific data for non-prescription products in order to authenticate a product’s claims.  DRP dermatologists evaluated Skinvisible’s scientific data and validated the following claims for DermSafe Hand Sanitizer: DermSafe is alcohol-free, it offers protection from harmful bacteria, it resists wash-off and it provides a moisture barrier for the hands. DermSafe, marketed by Alto Pharmaceuticals in Canada, will soon display the DRP Seal on its promotional materials and packaging.

European Patent Office (EPO) In late September 2011 Skinvisible  announced the European Patent Office (EPO) issued a Notice of Intent to Grant European patent application number 02752847.0 pertaining to Skinvisible’s drug delivery system, Invisicare, which  is a drug delivery technology used in prescription, over-the-counter and cosmeceutical products.  The comprehensive patent protects Invisicare®  composition ,  method of combining polymers to make the Invisicare complex and the skin / medical conditions Invisicare is used for.   This patent provides protection with claims that were also patented in the other Invisicare international patents. This patent approval is a significant milestone for Skinvisible as multi-national pharmaceutical and consumer goods companies seeking products for global distribution will now have protected products to license from Skinvisible on four continents, covering over twenty-two countries. Invisicare patent coverage now includes Europe, plus previously  announced India, Australia, China, Japan, Hong Kong, Korea, Canada and the USA.   Skinvisible continues to proactively build and strengthen its global intellectual property portfolio with twenty-eight patents pending. All patents with Invisicare® are owned by Skinvisible.

Women’s  Choice Pharmaceuticals LLC and ProCort(R) In July 2011 Skinvisible announced that its licensee, Women’s  Choice Pharmaceuticals LLC, a specialty pharmaceutical company based in Gilbert, Arizona,  launched ProCort(R), Skinvisible’s first prescription product in the United States. ProCort(R) is a topical treatment for hemorrhoids formulated with Skinvisible’s patented polymer delivery system Invisicare(R). Invisicare enhances the delivery of active ingredients by controlling the release and provides superior binding properties. ProCort(R) is made of a combination of hydrocortisone acetate and pramoxine hydrochloride. ProCort(R), launched this week, is a prescription product focused on the women’s health market.

Mr. Howlett founded Skinvisible, Inc. in 1998. With over 30 years of entrepreneurial, business management and market initialization experience, he drives and directs the Company’s development and technology vision. He is adept at guiding emerging and publicly traded start-up companies through the stages of capital formation, strategic planning and business growth; specializing in venture capital financing. Mr. Howlett’s diversified background includes senior management, marketing, and sales positions with both established and start-up companies. For More Information read the January 2012 Letter to shareholders.

Watch the Bill Chippas Show Business Talk Radio , TV and News Program for more about Skinvisible Pharmaceuticals plus forex , equity investments, precious metals and short  term winning trades and news at 6:05 PM ET Thursday February 9, 2012 on WPSLTV.com, Listen Live from  6:05 PM ET till 7:00 PM ET at  http://www.billchippasshow.com

*Rule 17B Requirements — Disclosure of Payment for Investor Relations– Princeton Research has received 150,000 restricted shares from Skinvisible in exchange for investor relations services.

Share and Enjoy

Joe Salvani representing Intellicell BioSciences Inc. appeared on the Tuesday February 7 -2012 broadcast of the business talk Radio, TV and News Program – The  Bill Chippas Show – and gave  insight on IntelliCell BioSciences Inc, watch Tuesday’s Broadcast  of  ‘The  Bill Chippas Show’ with Investment Strategies  market analysis and news.

Podcast

IntelliCell BioSciences Inc., http://www.intellicellbiosciences.com (symbol SVFC) is a pioneering regenerative medicine company focused on the expanding regenerative medical markets. IntelliCell BioSciences develops a portfolio of products and services that targets a wide and diverse regenerative, preventative, and curative medical market including age related disease states to sports related injuries.

IntelliCell BioSciences Inc. has patent-pending process for a non-enzymatic method of deriving stromal vascular fraction from adipose tissue (your own fat).  IntelliCell’s process dramatically increases the yield by 10 to 20 times in manufacturing compared to methods in use today. These mixtures of cells have multiple functions and are highly integrated and it’s likely, more potent than the adipose stem cells by themselves.

IntelliCell BioSciences Inc offers Intellicell™, a treatment for the correction of lines, wrinkles, and dermal defects, as well as for various treatments, including anti-aging, scarring, burns, and non-healing wounds; stem cell product candidates for treating aging dermal skin; and product candidates in the areas of osteoarthritis, cartilage and meniscus regeneration, and general dermal regeneration, the applications for its product are wide and diverse, IntelliCell BioSciences, Inc. is based in New York, New York.

IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients. The company is also setting up Centers of Excellence where doctors can treat their patients.  IntelliCell announced last month it licensed its proprietary, patent pending technology to RegenaStem Inc., a Canadian Federally Incorporated Company, with offices in Ontario, The license calls for investing a minimum of $500,000 to a maximum of $1.5 million into IntelliCell BioSciences and paying royalties of 30% of net revenue.

IntelliCell BioSciences is also starting FDA IND clinical trials at major medical centers for clinical indication approval, some potential centers are; Emory, Georgia Tech, Mt Sinai Medical Center , NYU and Tulane.  IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities.

For more information and insight on IntelliCell BioSciences listen or watch the Tuesday February  7-2012 Broadcast  of the business talk radio and TV program ‘The  Bill Chippas Show’ also get Investment strategies , market analysis and news , for additional information, visit http://www.intellicellbiosciences.com or call Princeton Research http://www.princetonresearch.com at 702-650-3000.

*Rule 17B Requirements — Disclosure of Payment for Investor Relations– Princeton Research has contracted to receive 10,000 restricted shares from IntelliCell BioSciences for  investor relations.

Share and Enjoy

*Rule 17B Requirements — Disclosure of Payment for Investor Relations– Princeton Research has contracted to receive 10,000 restricted shares from IntelliCell BioSciences for investor relations work.

Share and Enjoy

IntelliCell BioSciences Inc. will be featured on the Tuesday February 7, 2012 broadcast of the business talk Radio , TV and News program – The  Bill Chippas Show – to give insight on IntelliCell BioSciences Inc, watch Tuesday’s Broadcast  of  ‘The  Bill Chippas Show’ from 10:05 AM ET to 11:00 AM. Live on WPSLTV.com, get Investment strategies , market analysis and news at http://www.wpsltv.com , you may also listen live at http://www.billchippasshow.com , call in your questions to 772-340-1590 email questions bill@billchippasshow.com.
Joining the show will be Joe Salvani to provide information and the investment potential of IntelliCell BioSciences Inc. (symbol SVFC)

IntelliCell BioSciences Inc., http://www.intellicellbiosciences.com (symbol SVFC) is a pioneering regenerative medicine company focused on the expanding regenerative medical markets. IntelliCell BioSciences develops a portfolio of products and services that targets a wide and diverse regenerative, preventative, and curative medical market including age related disease states to sports related injuries.

IntelliCell BioSciences Inc. has patent-pending process for a non-enzymatic method of deriving stromal vascular fraction from adipose tissue (your own fat).  IntelliCell’s process dramatically increases the yield by 10 to 20 times in manufacturing compared to methods in use today. These mixtures of cells have multiple functions and are highly integrated and it’s likely, more potent than the adipose stem cells by themselves.

IntelliCell BioSciences Inc offers Intellicell™, a treatment for the correction of lines, wrinkles, and dermal defects, as well as for various treatments, including anti-aging, scarring, burns, and non-healing wounds; stem cell product candidates for treating aging dermal skin; and product candidates in the areas of osteoarthritis, cartilage and meniscus regeneration, and general dermal regeneration, the applications for its product are wide and diverse, IntelliCell BioSciences, Inc. is based in New York, New York.

IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients. The company is also setting up Centers of Excellence where doctors can treat their patients.  IntelliCell announced last month it licensed its proprietary, patent pending technology to RegenaStem Inc., a Canadian Federally Incorporated Company, with offices in Ontario, The license calls for investing a minimum of $500,000 to a maximum of $1.5 million into IntelliCell BioSciences and paying royalties of 30% of net revenue.

IntelliCell BioSciences is also starting FDA IND clinical trials at major medical centers for clinical indication approval, some potential centers are; Emory, Georgia Tech, Mt Sinai Medical Center , NYU and Tulane.  IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities.

For more information and insight on IntelliCell BioSciences listen or watch tuesday’s Broadcast of the business talk radio , TV and news program  The Bill Chippas Show’ from 10:05 AM ET to 11:00 AM on tuesday February 7, th 2012 Live on WPSLTV.com  http://www.wpsltv.com, also get Investment strategies , market analysis and news , for additional company information, visit http://www.intellicellbiosciences.com or call Princeton Research http://www.princetonresearch.com
at 702-650-3000.

*Rule 17B Requirements — Disclosure of Payment for Investor Relations– Princeton Research has contracted to receive 10,000 restricted shares from IntelliCell BioSciences to do investor relations.

Share and Enjoy